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FIGURE 1 Uncertain Length Measurements by Optical Coherence Tomography
Two consecutive corresponding optical coherence tomography acquisitions of the same section showing catheter motion artifact with
differences in elongation and compression between the 2 pullbacks.
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1715–7.REPLY: Triple Antithrombotic TherapyFollowing Anterior ST-Segment Elevation
Myocardial InfarctionWe thank Drs. Potter and Bastiany (1) for their interest
in our paper (2). We compared patients with anterior
ST-segment myocardial infarction managed with pri-
mary percutaneous coronary intervention (PCI) who
were subsequently prescribed warfarin to patients
who were not. We excluded patients with left ven-
tricular thrombus found on a transthoracic echocar-
diogram (TTE). The primary outcome was a composite
of net adverse clinical events (NACE) consisting
of all-cause mortality, stroke, reinfarction, or major
bleeding at 180 days of the TTE.
The propensity score was derived by ﬁtting a
multivariable logistic regression model where treat-
ment (warfarin vs. no warfarin) was used as the
outcome. The derived propensity score was then used
to derive the weights for the inverse probability
weighting logistic regression model where NACE was
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1137used as the outcome and warfarin as the independent
variable. In addition, a multivariable analysis using a
logistic regression model was performed to determine
the independent effect of adding warfarin therapy on
NACE. The apical score, left ventricular ejection
fraction, and the presence of cardiogenic shock were
entered into the model.
In patients deemed not to require oral anticoagu-
lants, heparin was discontinued immediately after
the TTE; however, heparin was continued as bridging
therapy in patients to be started on warfarin. The
decision to start warfarin exposed patients to full-
dose anticoagulation therapy during the hospital
stay, and therefore, it is appropriate to count events
that occurred during this interval.
By propensity score analysis, allocation to
warfarin therapy was an independent predictor of
NACE (odds ratio [OR]: 4.01, 95% conﬁdence interval
[CI]: 2.15 to 7.50, p < 0.0001). In a separate multi-
variable analysis, the odds of NACE remained
signiﬁcantly higher in comparison to patients who
were not prescribed warfarin (OR: 3.13, 95% CI: 1.34
to 7.22, p ¼ 0.007). In conclusion, our results do notsupport the addition of warfarin therapy following
primary PCI in patients with apical akinesis or
dyskinesis.*Michel Le May, MD
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